These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

421 related articles for article (PubMed ID: 15307033)

  • 21. Safety and immunogenicity of Towne cytomegalovirus vaccine with or without adjuvant recombinant interleukin-12.
    Jacobson MA; Sinclair E; Bredt B; Agrillo L; Black D; Epling CL; Carvidi A; Ho T; Bains R; Girling V; Adler SP
    Vaccine; 2006 Jun; 24(25):5311-9. PubMed ID: 16701925
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Antigen-specific T cell responses induced by Towne cytomegalovirus (CMV) vaccine in CMV-seronegative vaccine recipients.
    Jacobson MA; Sinclair E; Bredt B; Agrillo L; Black D; Epling CL; Carvidi A; Ho T; Bains R; Adler SP
    J Clin Virol; 2006 Mar; 35(3):332-7. PubMed ID: 16387547
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Protection against congenital cytomegalovirus (CMV) disease, conferred by a replication-disabled, bacterial artificial chromosome (BAC)-based DNA vaccine.
    Schleiss MR; Stroup G; Pogorzelski K; McGregor A
    Vaccine; 2006 Sep; 24(37-39):6175-86. PubMed ID: 16879902
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Physical and intellectual development in children with asymptomatic congenital cytomegalovirus infection: a longitudinal cohort study in Qinba mountain area, China.
    Zhang XW; Li F; Yu XW; Shi XW; Shi J; Zhang JP
    J Clin Virol; 2007 Nov; 40(3):180-5. PubMed ID: 17919973
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Congenital cytomegalovirus infection.
    Syggelou A; Iacovidou N; Kloudas S; Christoni Z; Papaevangelou V
    Ann N Y Acad Sci; 2010 Sep; 1205():144-7. PubMed ID: 20840266
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Cytomegalovirus vaccines and methods of production (WO20009049138): the emerging recognition of the importance of virus neutralization at the epithelial/endothelial interface.
    Schleiss MR
    Expert Opin Ther Pat; 2010 Apr; 20(4):597-602. PubMed ID: 20302454
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Progress toward developing a cytomegalovirus vaccine.
    Marshall GS; Plotkin SA
    Infect Dis Clin North Am; 1990 Jun; 4(2):283-98. PubMed ID: 2161034
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Review of Mathematical Models of Vaccination for Preventing Congenital Cytomegalovirus Infection.
    Lanzieri TM; Gastañaduy PA; Gambhir M; Plotkin SA
    J Infect Dis; 2020 Mar; 221(Suppl 1):S86-S93. PubMed ID: 32134475
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The immunological underpinnings of vaccinations to prevent cytomegalovirus disease.
    McCormick AL; Mocarski ES
    Cell Mol Immunol; 2015 Mar; 12(2):170-9. PubMed ID: 25544503
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Cytomegalovirus vaccines: current status.
    Starr SE
    Infect Agents Dis; 1992 Jun; 1(3):146-8. PubMed ID: 1365538
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Vaccine value profile for cytomegalovirus.
    Boppana SB; van Boven M; Britt WJ; Gantt S; Griffiths PD; Grosse SD; Hyde TB; Lanzieri TM; Mussi-Pinhata MM; Pallas SE; Pinninti SG; Rawlinson WD; Ross SA; Vossen ACTM; Fowler KB
    Vaccine; 2023 Nov; 41 Suppl 2():S53-S75. PubMed ID: 37806805
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Antiviral therapy of congenital cytomegalovirus infection.
    Schleiss MR
    Semin Pediatr Infect Dis; 2005 Jan; 16(1):50-9. PubMed ID: 15685150
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Epidemiology, pathogenesis and prevention of congenital cytomegalovirus infection.
    Burny W; Liesnard C; Donner C; Marchant A
    Expert Rev Anti Infect Ther; 2004 Dec; 2(6):881-94. PubMed ID: 15566332
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Detection of cytomegalovirus infection during a vaccine clinical trial in healthy young women: seroconversion and viral shedding.
    Zhang C; Buchanan H; Andrews W; Evans A; Pass RF
    J Clin Virol; 2006 Mar; 35(3):338-42. PubMed ID: 16388984
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Sensorineural hearing loss in childhood: evaluation of economic impact in view of vaccine prevention of cases due to congenital cytomegalovirus infection].
    Caroppo MS; Tanzi ML; Veronesi L; Ambrosetti U; Cislaghi C; Barbi M
    Ann Ig; 2005; 17(4):307-11. PubMed ID: 16156390
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Review and meta-analysis of the epidemiology of congenital cytomegalovirus (CMV) infection.
    Kenneson A; Cannon MJ
    Rev Med Virol; 2007; 17(4):253-76. PubMed ID: 17579921
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Scientific and Regulatory Considerations for Efficacy Studies of Cytomegalovirus Vaccines.
    Krause PR; Roberts J
    J Infect Dis; 2020 Mar; 221(Suppl 1):S103-S108. PubMed ID: 32134485
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The March towards a Vaccine for Congenital CMV: Rationale and Models.
    Bialas KM; Permar SR
    PLoS Pathog; 2016 Feb; 12(2):e1005355. PubMed ID: 26866914
    [No Abstract]   [Full Text] [Related]  

  • 39. Multi-antigenic human cytomegalovirus mRNA vaccines that elicit potent humoral and cell-mediated immunity.
    John S; Yuzhakov O; Woods A; Deterling J; Hassett K; Shaw CA; Ciaramella G
    Vaccine; 2018 Mar; 36(12):1689-1699. PubMed ID: 29456015
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Priorities for CMV vaccine development.
    Krause PR; Bialek SR; Boppana SB; Griffiths PD; Laughlin CA; Ljungman P; Mocarski ES; Pass RF; Read JS; Schleiss MR; Plotkin SA
    Vaccine; 2013 Dec; 32(1):4-10. PubMed ID: 24129123
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 22.